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Abstract
These proceedings summarize the insights shared by nationally renowned panels of experts and overall
themes discussed throughout a substance use disorder conference held at the University of Pennsylvania. The
conference included experts from academia and public and private sectors, who came together to discuss the
gaps in evidence-based substance use policy and practice, with particular emphasis on the opioid epidemic.
The day concluded with an interactive session focused on the exchange of ideas and solutions to curb the
opioid epidemic. Those ideas are included in these proceedings
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Substance Use Disorder in America: Research to Practice, and Back Again
Addressing the Gaps in Evidence-Based Policy and Practice 
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On June 9, 2017, 110 invited health researchers, clinicians, policymakers, health system leaders, and other stakeholders met at the University of Pennsylvania to discuss approaches to address the gaps in evidence-based substance use  
disorder policy and practice, with an emphasis on the current opioid epidemic. The conference was sponsored by the Center 
for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH), a NIDA-funded Center 
of Excellence, and hosted by the Leonard Davis Institute of Health Economics (LDI).
The goal of the conference was to bring together policymakers, who make decisions about, and researchers, who study, the 
treatment of substance use disorder (SUD) in the United States within the context of the current opioid epidemic.  
Specifically, this conference was designed to improve the translation of current research for policy stakeholders and to  
inform future research so that it can be responsive to policymakers’ needs. The conference began with a plenary that  
included a dynamic discussion about the history and scope of SUD. Conference breakout sessions covered the most pressing 
issues concerning opioid prescribing, evidence-based treatment of opioid use disorder, and the need to integrate treatment 
into the health system. The first set of breakout sessions were led by policymakers and the second by researchers. The  
conference participants then came together as one group for the keynote speaker, former Congressman Patrick Kennedy, 
who passionately shared his pursuit of insurance coverage parity for mental health and substance use treatment. The day 
concluded with an interactive session focused on exchanging policy ideas and solutions to curb the opioid epidemic.
Bruce Schackman, PhD, Principal Investigator and Director of CHERISH, welcomed the attendees and introduced CHERISH 
and its mission: to develop and disseminate health economic research on health care utilization, health outcomes, and 
health-related behaviors that informs SUD treatment policy and HCV and HIV care of people with SUDs. Zachary F. Meisel, 
MD, MPH, MSHP, Director of the CHERISH Policy and Dissemination Core, introduced the aims of the Core and conference: 
to improve the use and usefulness of policy-relevant and health economic research regarding SUD treatment.
Opening Plenary
The conference started with a plenary moderated by Daniel Polsky, PhD, LDI Executive Director. Panelists presented opening 
remarks:
A. Thomas McLellan, PhD, Co-founder of Treatment Research Institute, and former Science Advisor and Deputy Director of 
the White House Office of National Drug Control Policy, reviewed the history of SUD. For centuries, he explained, substance 
use has been considered “bad conduct” and has been addressed as a criminal justice issue. As a result, SUD has been  
treated and financed differently from other health conditions. Medical providers are not trained in SUD and treatment has 
only recently been covered by insurance. Dr. McLellan described opportunities for improvement in several policies and  
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practices, including educating the medical community (in the medical school curriculum) about SUD, working with insurance  
companies to ensure SUD coverage is based on evidence-based treatments, and informing and engaging consumers about 
SUD treatment. 
Richard G. Frank, PhD, Margaret T. Morris Professor of Health Economics in the Department of Health Care Policy at Harvard 
Medical School, and Former Assistant Secretary for Planning and Evaluation in the U.S. Department of Health and Human  
Services, described the role of a researcher in public policy. He compared the environments of a researcher and policymaker, 
particularly focusing on the pace of work. He said that in government, an individual must work quickly to address difficult 
problems, often without a good, clean design. Dr. Frank discussed his own experience at the Centers for Medicare &  
Medicaid Services (CMS), where he focused on ex-offenders – a population with an overdose rate three times higher than the 
national average. Studies had shown that early engagement of these individuals resulted in both better health and economic 
outcomes. His team pulled all of that evidence together and convinced the CMS Administrator, the Attorney General, and 
White House officials that this was good policy based on economic and clinical evidence. He concluded that this was an  
opportunity to use research as the foundation to secure access to health care for high-risk individuals without requiring  
further legislation. 
Joshua M. Sharfstein, MD, Associate Dean, Public Health Practice and Training at Johns Hopkins Bloomberg School of Public 
Health, and Former Principal Deputy Commissioner of the U.S. Food and Drug Administration, highlighted stigma and public 
misconceptions as a major concern. Dr. Sharfstein explained that people only look at outcomes they personally care about. 
Research can provide great evidence, but we must address this “block” that occurs when people do not hear the outcomes 
they want. Dr. Sharfstein called for research that explores effective delivery of evidence-based information to communities. 
He shared his own story of his time as health commissioner of Baltimore, when he worked with policymakers and clinicians 
to increase the number of buprenorphine prescribers. The intervention expanded SUD treatment, leading to fewer drug 
overdoses. Yet, better outcomes weren’t enough to convince everyone: the media still portrayed buprenorphine as the  
“new drug on the street that the government put there.” Dr. Sharfstein concluded that research evidence needs to be  
contextualized within a coherent narrative, so that policymakers (and the public) can extract meaning from the findings.
Responding to questions from the audience, the panel discussed barriers to treatment. Inpatient beds, they said, represent 
very little of the treatment need. The panel agreed that treatment must be evidence-based and meet patients’ needs. The 
panel admitted that substance use policies are often based on public perception, rather medical evidence. They suggested 
that payers (insurers) provide coverage based on the evidence of treatment. The panel concluded with thoughts on  
collaboration between researchers and decision makers. They stressed the importance of engaging and networking with 
others outside your own field of work. Researchers must be willing to engage with policymakers to better understand the 
practical research needs.
Breakout Group 1: Health Systems: Diagnosis and Treatment
Policy PersPectives
Jeffrey Samet, MD, Professor in General Internal Medicine and Professor of Public Health at Boston University, moderated 
the panel discussion. 
Jack Stein, PhD, Director of the Office of Science Policy and Communications at the National Institute on Drug Abuse (NIDA), 
reviewed the Department of Health and Human Services’ (HHS) comprehensive opioid strategy. The strategy includes 
strengthening public health surveillance, advancing the practice of pain management, improving access to treatment,  
increasing availability of overdose-reversing drugs, and supporting cutting-edge research. NIH research initiatives focus on 
safe and effective pain management strategies, innovative medications and technologies, and interventions that reduce  
mortality. Dr. Stein highlighted new treatments, including emergency department-initiated buprenorphine, naltrexone in 
criminal justice populations, and a fentanyl vaccine in development. Dr. Stein also introduced the importance of  
public-private relationship and the development of cascade-of-care models that shift treatment services from a pay scale  
to a value scale.
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Hillary Kunins, MD, Assistant Commissioner at the New York City Department of Health and Mental Hygiene, discussed 
responding to the community’s needs. Dr. Kunins said that New York City has enough resources to accommodate most 
patients, but stigma continues to deter many. She encouraged the development of flexible harm reduction and treatment 
strategies that operate within an integrated system of health care delivery. Dr. Kunins added that it is important to  
understand that individuals will use both harm reduction and treatment systems simultaneously, and ultimately, we must 
meet the patients where they are.
Colleen LaBelle, MSN, RN-BC, Program Director, Clinical Addiction Research and Education (CARE) Unit at Boston  
University, expressed concern with current opioid policies. She pointed out that policy is not based on evidence and instead 
often creates a barrier to treatment. Specifically, she discussed the regulation of buprenorphine. Ms. LaBelle reviewed state 
and federal regulations that further contribute to the limited availability of providers for medication-assisted treatment 
(MAT), including prescribing restrictions placed on nurse practitioners.
research PersPectives 
Marcus Bachhuber, MD, Assistant Professor at the Albert Einstein College of Medicine, moderated the panel discussion.
Kathy Bradley, MD, Senior Investigator at the Group Health Research Institute and Affiliate Professor in Medicine and  
Health Services at the University of Washington, discussed her clinical trial to treat opioid use disorder in primary care.  
She explained that when a primary care clinic becomes self-sufficient (staffed with independent, knowledgeable MAT  
providers), it has transformative effects on SUD treatment outcomes. She elaborated on the importance of integrating  
behavioral health into primary care as well as using social marketing to normalize and destigmatize SUD in the health  
domains. The success of buprenorphine and MAT among patients in the trial changed perceptions among clinic health  
care workers who were initially resistant to treating SUD patients. 
Adam Gordon, MD, Professor of Internal Medicine and Psychiatry at the University of Utah, focused on the role of MAT. Dr. 
Gordon posed several complex research questions to contextualize this issue: Can MAT fill the need for treatment in rural 
areas? Does the duration of MAT affect patient outcomes? Who is responsible for prescribing MAT through Medicaid and 
what patients qualify? Further expanding on the complexity, Dr. Gordon spoke about the nuances that make access to  
long-term SUD treatment challenging for most who need it.
Jennifer McNeely, MD, Assistant Professor at the New York University School of Medicine in the Department of Population 
Health, examined the value of SUD screening. She explained how screening tools should be assessed on a continuum, in 
which resources can then be provided accordingly. She emphasized that these resources should be evidence-based and  
convenient for self-administration. Dr. McNeely stated that, despite existing screening tools that would be effective  
assessments in clinical settings, the challenge is with implementation.
Breakout Group 2: Opioid Prescribing: Striking a Balance
Policy PersPectives
Michael Ashburn, MD, Director of Penn Pain Medicine Center and Professor of Anesthesiology and Critical Care at the  
University of Pennsylvania moderated the panel discussion.
Rita Noonan, PhD, Branch Chief, Health Systems and Trauma Systems Branch, Centers for Disease Control and Prevention 
(CDC), gave an overview of the opioid epidemic. Opioid prescribing increased dramatically during the 1990s, and the  
United States remains far above the rest of the world in opioid prescriptions sold. She identified two groups with very  
different needs: those who need access to services and those who are at risk for SUD. Dr. Noonan explained five policy  
domains that must be addressed, including: (1) improving prescribing for pain, (2) improving management of addiction,  
(3) partnering with law enforcement, (4) cultivating community awareness and support (for example, notifying users of  
dangerous fentanyl batches), (5) rigorous, real-time monitoring of overdoses, with adaptive responses. Dr. Noonan also  
discussed supply side strategies, such as prescription drug monitoring programs (PDMP) and pain clinic regulations to 
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prevent so-called “pill mills.” Supply side strategies aim to mitigate the risk of an individual developing an SUD. She further 
discussed demand side strategies, targeting those who need treatment and other support. 
Jean Bennett, PhD, Substance Abuse and Mental Health Services Administration (SAMSHA) Regional Administrator,  
highlighted opportunities, challenges, and research needs of policymakers as they relate to opioid prescribing. Dr. Bennett 
discussed her approach to incorporating pain practice into medical schools: empowering school leaders to develop the 
new curriculum. She reviewed ongoing research conducted by SAMHSA, including multiple publications focused on health 
economics and opioid use disorder.
Rachel Levine, MD, the Pennsylvania Physician General, shared the Commonwealth’s viewpoint and points of emphasis. Dr. 
Levine said that in 2016, 4,812 people died from drug overdoses in Pennsylvania, a 27% increase from 2015. Dr. Levine also 
discussed the concept of opioid stewardship. She explained that providers must learn to prescribe opioids more cautiously, 
understanding that there is a time and a place for the treatment. She compared this to reducing the use of antibiotics due 
to concerns about antibiotic resistance. The Pennsylvania Department of Health has additional opioid prescribing  
guidelines that expand on the CDC recommendations, including specialty areas such as orthopedics, obstetrics and  
emergency medicine. Pennsylvania has three ongoing initiatives: (1) a prescription drug monitoring program (PDMP) that 
went live in August 2016, (2) the Physician General’s standing order (for open prescriptions) for Naloxone at pharmacies, 
and (3) “warm hand offs” from the emergency departments (ED) to coordinate care for drug overdose patients and link 
them to substance use treatment programs. Additionally, the state has introduced Pennsylvania Coordinated Medication 
Assisted Treatment (PacMAT), a hub and spoke network that connects primary care physicians to a SUD expert who can help 
answer questions and concerns regarding prescribing MAT and facilitate SUD treatment. 
research PersPectives 
Yuhua Bao, PhD, Associate Professor of Healthcare Policy and Research at Weill Cornell Medical College, moderated the 
panel discussion.
Deborah Dowell, MD, Senior Medical Advisor, CDC Division of Unintentional Injury Prevention, discussed the “CDC  
Guideline for Prescribing Opioids for Chronic Pain.” Dr. Dowell was the lead author of the guideline, published in 2016. She 
reviewed current literature on opioid use for pain management. The CDC guideline concludes that opioids are modestly 
effective in reducing severe, acute pain, and pain associated with cancer, but have no established benefits of long-term 
use for non-cancer pain. Dr. Dowell also shared evidence that longer durations and higher doses of prescription opioids are 
associated with the development of opioid use disorder. Dr. Dowell presented studies that showed that pain, function, and 
quality of life of chronic opioid users improved with opioid dose reduction or discontinuation with support. One caveat: 
these randomized controlled trials were studied with motivated users, defined as those who want to cut down their  
opioid use.
Dan Hartung, PharmD, Associate Professor in the College of Pharmacy at Oregon State University, presented his research 
on Medicaid pharmacy benefits as a strategy to reduce opioid prescribing. These strategies include:
 (1) Preferred drug lists (formularies)
 (2) Quantity limits (46 states)
 (3) Prior authorization (45 states)
 (4) Point of Service (POS) adjudicated clinical criteria (42 states)
 (5) Step therapy, requires short-acting opioids prior to long-acting (32 states) 
 (6) Lock in programs (46 states)
 (7) Dosage limits
 (8) Required use of PDMP (26 states)
Dr. Hartung presented limitations to research utilizing claims data, as this information does not capture out-of-pocket costs. 
His research showed that 13.5% of PDMP opioid fills of Medicaid beneficiaries were paid out-of-pocket. Patients paying 
out-of-pocket can circumvent policies (such as prior authorization) and is a limitation to future claims data-based policy 
evaluations. He also suggested that sharing PDMP data between states can help to capture “unobserved” opioid use.  
Dr. Hartung stated that there is a diversity of pharmacy benefit strategies to reduce high-risk opioid prescribing but most 
remain understudied. 
Stefan Kertesz, MD, Associate Professor, Division of Preventive Medicine at the University of Alabama at Birmingham School 
of Medicine, stated that while the CDC Guideline for Prescribing Opioids for Chronic Pain was a serious response to a  
serious problem, it may have had some unintended consequences. Policymakers and providers, he said, do not follow 
the guidelines correctly and often go too far in limiting opioid prescriptions for patients who may need them. Dr. Kertesz 
suggested opioid prescription policy is not simply “pill control,” and policies should not focus on the amount of opioid 
prescribed, without evidence. He specifically reviewed the seventh recommendation outlined in the CDC guidelines, which 
addresses patients already on an opioid-based therapy for chronic pain. The guideline recommends that this population be 
evaluated for the benefits and harms of continued opioid use. Dr. Kertesz noted that providers already do this with other 
chronic medical conditions, such as hyperlipidemia (high cholesterol), where treatment is based on multiple risk factors. 
He highlighted a major limitation to studies on opioid tapers and discontinuations, as these studies include only motivated 
patients, who want to reduce their opioid consumption. Dr. Kertesz stated it is important to clarify this recommendation. He 
suggested that while payers (insurance companies) and providers should embrace risk mitigation, legislation should not use 
target numbers (such as morphine equivalents) as policy. He also suggested that there is more nuance to these chronic pain 
patients and that a dosage limit can have severe unintended harms.
Breakout Group 3: Treatment: Access, Coverage, Quality, Costs
Policy PersPectives
Gary Mendell, Founder and CEO of Shatterproof, moderated the panel discussion. He set the tone of the discussion by 
contrasting how a patient is compassionately treated for cancer and how a highly stigmatized patient is treated for SUD. 
Panelists addressed problems of access, coverage, quality, and costs through a policy perspective.
A. Thomas McLellan, PhD, co-founder of the Treatment Research Institute provided several different ways of thinking about 
treatment. Because patients, during treatment, often feel recovered and thus do not seek further outpatient care, insurers 
and payers need to incentivize continuity of care. To describe the treatment sector as it is now, Dr. McLellan used a  
metaphor that resonated in the room: he compared the lack of a full continuum of care to the inability of a car to run.  
All of the parts needed for continuity of care are already present in our health care system, just as the car’s parts are in a 
shop. But to have the desired full continuum of care (or a working car), there must be standardization and mutual  
understanding among stakeholders to bring all these parts together. Dr. McLellan noted that these parts can only be  
synchronized once consumer value is identified.
John O’Brien, MS, Senior Consultant in the Human Services Group at the Technical Assistance Collaboration, built upon Dr. 
McClellan’s remarks and talked about how to maintain quality treatment after people obtain coverage. He offered solutions 
that have worked in the past, such as regulation and litigation, but he placed particular focus on the need for public  
education to reduce stigma and payment reforms that would lower financial barriers to treatment. As of now, he argued, 
these two policy approaches are largely nonexistent. 
In response to audience questions, Dr. McLellan and Mr. O’Brien clarified what it means to have access to SUD treatment, 
both in numbers and concept. Of the 23-25 million people diagnosed with moderate to severe substance abuse disorders 
(12 years and older), about 10% receive specialty treatment. The panel emphasized that 90% of the treatment received 
is outpatient, raising a myriad of issues from physical proximity to a health center to insurance coverage and continuity of 
care. Discussion further centered on prioritizing insurance and Medicaid payments for evidence-based treatments. The  
panelists illustrated the deficiencies in care. Most detoxification centers do not have follow-up and continuity of care, with 
60% of patients expected to relapse in three months and 80% in six months. The panelists agreed that society will not be 
able to treat itself out of the opioid epidemic without early-stage interventions and prevention strategies in place.
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research PersPectives
Brendan Saloner, PhD, Assistant Professor in the Bloomberg School of Public Health at Johns Hopkins University, moderated 
the panel discussion.
Richard Frank, PhD, the Margaret T. Morris Professor of Health Economics at Harvard Medical School, provided a diverse 
statistical picture of the SUD epidemic in America. Rates of SUD are 30%-50% higher in low-income brackets, and only 26% 
of people with an opioid use disorder are treated. Dr. Frank outlined the reasons for individuals not receiving treatment: 
cost/affordability, 36%; availability, 16%; stigma, 22%; not ready to stop, 29+%.
Dr. Frank also noted that we have not seen an upswing of people treated in specialty programs, but we have seen an  
upswing in medication-assisted treatment. On an optimistic note, he argued that, despite the current political climate, SUD 
is free from “disfiguring” politics, with Medicaid becoming a quiet model of bipartisanship and the basis for expanding  
behavioral treatments.
Tami Mark, PhD, Senior Director of Behavioral Health at the Research Triangle Institute (RTI) International, discussed the 
history of Prozac as an example of how a new, effective medication can improve rates of treatment. After Prozac entered the 
market, she said, the rate of mental health treatment doubled. Dr. Mark believes that developing more effective  
medications is key to “solving” the SUD epidemic, and that the lessons of Prozac may apply to buprenorphine prescribing. 
She also emphasized the importance of paying attention to consumer demands, stating that consumers not only want  
medications that are safe and effective, but ones that make them feel better. Thus, she believes that drug agonists, such as 
buprenorphine, will ultimately be more desirable for patients than other treatment options.
Harold Pollack, PhD, the Helen Ross Professor in the School of Social Service Administration at the University of Chicago, 
explored the criminal justice system through his own research experiences at Cook County Jail in Chicago. The “Supportive 
Release Center” at Cook County was developed by his research team to help transition individuals with SUD after release. 
He was also involved in the Westside Narcotics Diversion and Treatment Initiative, where individuals with SUD were offered 
treatment as an alternative to prison. These initiatives, and others like them, can reduce recidivism and relapse rates. Dr. 
Pollack also spoke about Medicaid expansion, which he credited with making effective and comprehensive treatment  
possible. Lastly, Dr. Pollack urged the audience to have open dialogues with patients to better understand what they value 
most regarding screening and treatment.
In response to audience questions, the panel discussed Medicaid expansion and the impact of stigma on treatment access. 
The panel also discussed the current detox model and the feasibility of emergency room induction of MAT. Smoking was 
also used as a comparison to opioid use. Despite long-term consumption and individual value placed on smoking, people 
quit tobacco use for health, cosmetic, and other concerns. To motivate patients to seek treatment, the panel said,  
researchers must help identify what individuals value.
Keynote Address: Congressman Patrick Kennedy
Patrick Kennedy, former United States Representative and Co-Founder of One Mind, and Founder of the Kennedy Forum, 
gave the keynote address. The Congressman discussed mental health parity. He highlighted four key areas for advancing the 
treatment for substance use and other mental health disorders, including:
 •   quality and transparency
 •   brain health and fitness
 •   technology
 •   integration and coordination
Congressman Kennedy was very forthcoming about his own experiences with SUD. Despite some unexpected community 
support, he experienced barriers to advancing mental health reform due to stigma. He notes that stigma impacts politics, 
and without “political will” any policy proposal discussed at the conference cannot take root and grow. He believes our 
LDI/CHERISH Conference Proceedings  |  6
LDI/CHERISH Conference Proceedings  |  7
current system is viewed “microscopically,” and that we lose the common narrative that substance use and mental health 
disorders affect every family. He believes the government is more likely to pass legislation as a result of moral obligation, 
rather than pure economic reasoning. He noted that we must put evidence and policy ideas in terms that will resonate with 
people. 
CHERISH Needs Assessment Presentation
Zachary F. Meisel, MD, MPH, MSHP, Director of the CHERISH Dissemination and Policy Core discussed the findings of the 
CHERISH needs assessment. As part of the research program embedded within the Policy and Dissemination core,  
investigators conducted in-depth interviews with research end users that focused on identifying their needs for  
economic research to make informed policy decisions. With the help of the Center’s Policy Advisory Board, the investigators 
used snowball sampling to enroll 18 informants. An interview guide, informed by Mitton’s knowledge transfer framework of 
evidence-based policy, was designed and piloted to explore the barriers and facilitators to the adoption and use of economic 
research for the treatment of these conditions within the context of the evolving health care system. Individuals from  
government, integrated health systems, private health insurance, the pharmaceutical industry, clinical care, and patient  
advocacy were interviewed by staff trained in qualitative research methods. Four main themes emerged from the analysis  
of the interviews. 
 •   Engagement with evidence: interviewees recommended early, ongoing, cultivated and informal relationships  
      between researchers and decision makers. 
 •   The use and usefulness of the research: interviewees asked for models and examples of evidence that spoke to 
      local needs.
 •   Jargon and language: interviewees rejected the jargon and overly technical aspects of health economic research,  
      especially if it made this evidence difficult to explain or summarize to peer stakeholders.
 •   Method and modes of communication from scholars to researchers: interviewees wanted to know more about 
      how the research was done and requested a contextual narrative to be able to understand and repurpose the  
      evidence for specific policy prescriptions.
Substance Use Disorder in America: Bridging the Gaps
The conference concluded with an interactive session focused on the exchange of ideas and solutions to curb the opioid 
epidemic. Attendees were asked to self-identify as a researcher or policymaker and sit at color-coded seat assignments 
designed to distribute researchers and policymakers equally among the 13 tables at the conference. Participants were 
shown a short video vignette featuring a woman sharing a true story about her daughter’s struggle with and eventual death 
from opioid use disorder. In the scenario, the family was referred to multiple inpatient treatment programs by their health 
insurance provider, in which MAT was discontinued and post treatment follow-up and care was not coordinated. Each table 
of 5-8 participants developed ideas to address the many complexities posed by this case, and then shared ideas with the 
larger group. After the conference, the ideas were summarized in the following categories and were ranked by conference 
attendees in a web-based evaluation form. The post-conference rankings are listed below:
Quality of treatment
 (1)   Tie insurer payment to minimum standards for treatment based on evidence-based practice and  
         continuity of care 
 (2)   Eliminate or reduce the burden of regulations of buprenorphine prescribing
 (3)   Create an independent accreditation body that both rates treatment facilities on meeting standards of care  
         and provides a complete listing of available treatment centers and their quality scores
continuity of care
 (1)   Assure in-person or telephone care coordination following discharge, through peer support or MAT providers 
 (2)   Promote the hub and spoke models (such as PacMAT), to ensure primary care physicians feel comfortable and 
         supported prescribing MAT 
 (3)   Promote emergency department induction of buprenorphine prior to discharge or hospital admission
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oPioid Prescribing / Pain management
 (1)   Require insurance companies to cover alternative pain treatment modalities, so that opioids are not the default  
         pain management 
 (2)   Tie the use and development of prescription guidelines to federal funding 
 (3)   Develop a state scorecard on prescribing that ranks the states in relation to their goals  
         (and holds governors responsible)
consumer engagement
 (1)   Create a centralized system of treatment facilities and providers where patients can sign up themselves 
         (Airbnb-type model) 
 (2)   Develop a family and consumer marketing campaign 
 (3)   Produce consumer-driven rating system or recorded metric of treatment programs 
 (4)   Fund programs that incentivize individuals into treatment (and start with research on best incentive programs)
Bruce Schackman, PhD, Principal Investigator of CHERISH, closed the conference by encouraging attendees to stay engaged 
with others in different fields, to continue the work toward the evidence-based policies and practices discussed during the 
conference, and to keep CHERISH informed of their progress to help the Center plan for next steps.
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